Lucrative Stocks Watch List - Springleaf Holdings, (NYSE:LEAF), Orexigen Therapeutics, (NASDAQ:OREX)

On Tuesday, Following U.S. Stocks were among the “Top Gainers”:Springleaf Holdings, (NYSE:LEAF), Orexigen Therapeutics, (NASDAQ:OREX)

Springleaf Holdings, (NYSE:LEAF), with shares inclined 2.58%, closed at $48.20.
Orexigen Therapeutics, (NASDAQ:OREX), with shares jumped 2.46%, settled at $7.30.

Latest NEWS regarding these Stocks are depicted underneath:

Springleaf Holdings, LLC (NYSE:LEAF)

Springleaf Holdings, LLC (LEAF), a leading consumer finance corporation providing loan products to customers nationwide, declared it is the primary sponsor of the 2015 Chicago River Dyeing, a celebrated local ritual that kicks off St. Patrick’s Day in Chicago. The dyeing of the river will commence at 9:15 a.m. CT, Saturday, March 14th, 2015 between Michigan Ave. and Columbus.

Led by the Local 130 U.A. Chicago Journeymen Plumbers Union, the dyeing of the Chicago River and the subsequent Chicago St. Patrick’s Day Parade has been a Chicago tradition for over 60 years. As the primary sponsor of the river dyeing event, Springleaf Financial will host the kick-off to St. Patrick’s Day with a “First Dye Can” ceremony to commemorate the first can of dye entering the river. Mike Walsh, Regional Vice President - Director of Operations at Springleaf Financial will lead the ceremony, and will be joined by Michele Scaccia of the St. Patrick’s Day Committee and Jim Coyne of the Chicago Plumbers Union. This will take place at 200 S. Wacker, Lower Level at 8:30 a.m. CT to kick off the St. Patrick’s Day festivities.

Springleaf Holdings, LLC, through its auxiliaries, offers consumer finance and credit insurance products and services. The corporation provides personal loans secured by automobiles, consumer household goods, and other items of personal property; and unsecured loans. It also writes credit life, credit accident and health, credit related property and casualty, and credit involuntary unemployment insurance products; non-credit insurance products; and ancillary products, counting home security and auto security membership plans, and home appliance service contracts of unassociated companies.

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Formerly on February 25, Orexigen Therapeutics, Inc. (OREX), declared business and financial results for the fourth quarter and year ended December 31, 2014.

Contrave (naltrexone HCl / bupropion HCl extended release):

Orexigen’s partner for North America, Takeda Pharmaceuticals, launched Contrave in the United States on October 20, 2014. U.S. net sales for the fourth quarter, recorded by Takeda, were $6.5 million, for which Orexigen earned $1.3 million in royalties. Gross sales for the quarter were $12.3 million.

Contrave is indicated as an adjunct to a reduced-calorie diet and raised physical activity for chronic weight administration in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).

Orexigen Therapeutics, Inc., a biopharmaceutical corporation, focuses on the development of pharmaceutical product candidates for the treatment of obesity.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content described in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.